European Biotech Act: Acceleration & Governance

At MyData-TRUST, the European Commission’s announcement of the European Biotech Act on 16 December 2025 represents a structural shift aimed at bolstering Europe’s biotechnology sector, with a particular emphasis on expediting patient access to new therapies, which is an exciting prospect welcomed by MyData-TRUST, although challenges in the EU’s implementation of the Act remain. This initiative marks a decisive step towards strengthening Europe’s position as a global biotech leader and, more importantly, a step towards accelerating patient access to transformative innovations.

The Commission’s intent is evident: to foster faster development, enhanced scalability, and global competitiveness in biotech, all underpinned by robust standards for trust, safety, and responsibility. MyData-TRUST is fully aligned with this direction, recognising that effective Data, Privacy, and AI governance will be pivotal to its realisation, which is based on our experience advising over 800 Life Sciences clients on similar regulatory transitions.

🎯 What the Biotech Act is aiming to achieve

The Biotech Act focuses primarily on health biotechnology, which accounts for the majority of the sector’s economic output and employment in the EU. It promotes innovation by targeting long-standing structural barriers such as regulatory fragmentation, protracted approval processes and timelines, and limited access to capital.

Key objectives include:

Reducing time to market for biotech products, particularly through accelerated and streamlined clinical trial authorisations.
Simplifying regulatory pathways, including the introduction of regulatory sandboxes for innovative and atypical trials.
Boosting biomanufacturing capacity and industrial capabilities in Europe.
Harnessing data, AI and digital technologies, notably through the European Health Data Space and trusted testing environments.
Strengthening biosecurity, with reinforced controls on sensitive sequences, access and misuse prevention.

This is an ambitious, ecosystem-wide reform touching clinical trials, advanced therapies, substances of human origin, data infrastructures and security frameworks.

📈 A Concrete acceleration of clinical development

One of the most tangible changes announced concerns clinical trial timelines.

The Commission proposes cutting multinational clinical trial authorisations:

from 75 to 47 days where no additional information is requested, and
from 106 to 76 days where clarifications are needed.

Similarly, timelines for substantial modifications would be almost halved in standard cases. This acceleration is excellent news for innovation and patients, but it also reshapes how projects are planned, governed and executed.

🔐 What this means for Data, Privacy and AI Governance

From a data governance perspective, the Biotech Act presents opportunities alongside hurdles, particularly in harmonising GDPR with the Act.

Acceleration compresses timelines

The faster pace of authorisations will mean that considerations such as Privacy by design, conducting DPIAs, vendor governance, assessing data transfers, and ensuring that security measures are adhered to will need to be embedded earlier and executed faster, without compromising their robustness.

Data and AI become central enablers

Data and AI emerge as core drivers, with the European Health Data Space enabling secondary use of Health Data under Regulation (EU) 2025/327, but only if quality, reuse terms, and compliance with the AI Act are managed cohesively; in practice, this could involve trusted environments for testing AI models in Life Sciences applications.

Biosecurity raises sensitive governance questions

Sequence screening, access controls and traceability mechanisms intersect Data Protection with ethics and compliance, requiring clear accountability across complex value chains such as biobanks, CROs, platforms and consortia.

In short, speed without governance is risk, and governance without speed is a missed opportunity. The Biotech Act challenges organisations to achieve both without compromising their obligations under existing regulations.

🛠️ How MyData-TRUST is preparing to support the ecosystem

At MyData-TRUST, this development prompts us to promote offerings, drawing upon our expertise developed and refined over 1800 Life Science compliance projects. We are incredibly well positioned to help biotech firms in adapting to these regulatory developments to avail from this promoted acceleration into operational success, reducing the time costs for our clients while maintaining trust and compliance.

Our focus areas include:

Fast track Privacy and AI governance adapted to accelerated clinical and R & D timelines.
DPIA and vendor governance models designed for complex biotech value chains.
Data and AI clauses tailored to biobanks, European Health Data Space use cases, sandboxes and collaborative research.
Privacy and ethics by design support for scientific committees, boards and innovation programmes.

We are already working on practical guidance, including a one pager on “What the Biotech Act changes for privacy governance in biotech”, and look forward to engaging with clients, partners and policymakers as the proposal evolves.

👉 Looking Ahead

The European Biotech Act is not just a regulatory reform, it is signalling a strategic pivot for Europe’s biotech landscape. Europe wants to promote innovation, speed and trust to promote the continent as the preeminent location for research.

At MyData-TRUST, we are viewing this as an opportunity as a catalyst for refined governance, and we are uniquely positioned to guide our clients through the regulatory complexities with targeted compliance strategies.

In essence, accelerating innovation requires structured safeguards; we’re equipped to deliver on that front.

Innovation deserves acceleration. Trust deserves structure. We are here for both.